Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Neoplasms 3Neuroblastoma 2Lung Neoplasms 2Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1ALK-positive Advanced Tumors 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × ceritinib × Clear all
NCT02780128 2026-03-10

NEPENTHE

Children's Hospital of Philadelphia

Phase 1 Terminated
66 enrolled
CNS

Neoplasms, Neuroblastoma

NCT02292550 2020-12-17

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Novartis

Phase 1 Completed
27 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed
83 enrolled 30 charts
CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡